This study is testing a drug called Artesunate to see if it is safe and tolerable for people with Idiopathic Pulmonary Fibrosis (IPF), a chronic lung disease that causes scarring and shortness of breath. You would receive either Artesunate capsules or placebo capsules (inactive medicine) by mouth twice daily. The Artesunate dose would increase every four weeks. The study aims to find out how many participants experience side effects from the treatment. To join, you must be at least 40 years old and have a diagnosis of IPF, with specific lung function test results (FVC and DLco). The study is currently unclear about its recruitment status and plans to enroll 15 participants.

Study design

This is a randomized, double-blinded, placebo-controlled study, meaning participants are randomly assigned to receive either the study drug or a placebo, and neither you nor your doctors will know which you are receiving. It will involve 15 participants.

What's involved

The study lasts 20 weeks, including up to 4 weeks for screening, 12 weeks of oral Artesunate or placebo treatment with dose escalation every 4 weeks, and a 4-week follow-up period.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 4 weeks after treatment, with adverse events measured at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.